Poster Abstract Session:
203. PK/PD Studies
Saturday, October 20, 2012: 12:30 PM-2:00 PM
Room: SDCC Poster Hall F-H

Topical Category: A. Antimicrobial Agents

Tracks: Adult ID

Presentations:

Impact of Initial Vancomycin AUC24h over MIC on Treatment Outcome in Methicillin-Resistant Staphylococcus aureus Bacteremia
Younghee Jung ; Shinhye Cheon ; Gayeon Kim, MD ; Yu Min Kang, MD ; Nak-Hyun Kim ; Kyoung-Ho Song, MD ; Ji-Whan Bang ; Eu Suk Kim ; Hong Bin Kim ; Sang-Won Park, MD, PhD ; Nam Joong Kim, MD, PhD ; Myoung-don Oh, MD, PhD
Posters
  • IDSA_2012_Poster.pdf (2.6 MB)

  • Pharmacokinetics (PK) and Pharmacodynamics (PD) of Extended-Infusion (EI) Piperacillin-Tazobactam (TZP) in Adult Patients (Pts) with Cystic Fibrosis (CF)
    Jill Butterfield, PharmD ; Thomas Lodise, Pharm D ; Scott Beegle, M.D. ; Jonathan Rosen, M.D. ; Joshua Farkas, M.D. ; Manjunath Pai, PharmD, BCPS

    Pharmacodynamic (PD) Profile of Once Daily Administration (ODA) of Tobramycin (TOB) in Adult Patients with Cystic Fibrosis (CF)-Acute Pulmonary Exacerbation (APE)
    Jill Butterfield, PharmD ; Thomas Lodise, Pharm D ; Manjunath Pai, PharmD, BCPS ; Jonathan Rosen, M.D. ; Joshua Farkas, M.D. ; Scott Beegle, M.D.

    Toxin Quantitation of Streptococcus pyogenes with exposure to daptomycin vs. clindamycin
    M Jahangir Alam, PhD ; Kevin W. Garey, PharmD, M.S. ; Kimberly Halton, PharmD ; Elizabeth Coyle, PharmD

    Pharmacokinetics (PK) of Daptomycin (D) in a Pooled Sample of Hemodialysis (HD) Patients (Pts)
    Jill Butterfield, PharmD ; Bruce Mueller ; Darren Grabe, PharmD ; Nimish Patel, PharmD ; Katie Cardone, PharmD ; Noha Salama, PhD ; Thomas Lodise, Pharm D

    The Impact of Body Mass Index (BMI) on the Pharmacokinetics of Daptomycin in Patients with Staphylococcus aureus Bacteremia
    John Mohr III, Pharm D ; Shruta Rege, PhD ; Pamela White, PharmD ; David Benziger, PhD ; Sara Yankelev, MS
    Posters
  • 2012100862v2_Layout 1.pdf (177.8 kB)

  • Population-based Pharmacokinetic Modeling of Vancomycin in Children with Renal Impairment
    Jennifer Le, PharmD, BCPS-ID, FCCP ; Emily Nguyen, PharmD ; Florin Vaida, PhD ; Felice C. Adler-Shohet, MD ; Jiah Kim ; Tiana Vo ; Edmund Capparelli, PharmD
    Posters
  • LeJ Vanco 1633.pdf (241.7 kB)

  • Efficacy, Safety, and Cost of Pharmacodynamic Dose Optimization of Beta-Lactam Antibiotics
    Nicholas J. Panno III, PharmD ; Tamara L. Trienski, PharmD ; Anthony Leung, DO, FACP, FASCP ; Dorcas Letting-Mangira, PharmD ; Timothy R. Pasquale, PharmD

    Population Pharmacokinetics (PK) of Lopinavir During Pregnancy and Postpartum
    Justin Hoffman, PharmD MS ; Brookie Best, PharmD ; Mark Mirochnick, MD ; Alice Stek, MD ; Jiajia Wang, MS ; Tim Cressey, PhD ; Edmund Capparelli, PharmD

    Risk Factors Associated with Systemic Absorption of Oral Vancomycin (POV) in the Treatment of Clostridium difficile Colitis (CDAD)
    Peggy L. Carver, PharmD, FCCP ; Daryl D. DePestel, PharmD, BCPS ; Natasha N. Pettit, PharmD, BCPS ; Alexander L Fohl, PharmD, BCPS ; Rachel Eyler, PharmD

    Association of Vancomycin Loading Dose with Nephrotoxicity
    Andrea Call, PharmD ; Russell Acevedo, MD ; Lynette Johnson, MS ; Waleed Javaid, MD
    Posters
  • Vanco Load Dose poster.pdf (310.0 kB)

  • Population Pharmacokinetics (PK) of Oral and Intravenously Administered Tedizolid Phosphate in Adolescent Patients
    Edmund Capparelli, PharmD ; Shawn Flanagan, PhD ; John S. Bradley, MD, FIDSA ; Antonio Arrieta, MD ; Richard Jacobs, MD ; Kelly Ann Munoz ; Howard Dreskin ; Edward Fang, MD ; Philippe Prokocimer, MD

    Serum Inhibitory and Bactericidal Activity of Telavancin in Patients with Severe Renal Impairment
    S Barriere, PharmD ; DJ Farrell, Ph.D. ; Paul Rhomberg ; Ronald Jones, MD

    Improving Weight-Based Vancomycin Dosing and Monitoring
    Heta Javeri, MD, MPH ; Bin Xiao, PharmD ; James S. Lewis II, PharmD, FIDSA ; Darrel W. Hughes, PharmD ; Elizabeth Walter, MD
    Posters
  • IDSAvanc_PDF.pdf (322.7 kB)
  • CME Credits:


    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.